Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new topical corticosteroid.
Diflorasone diacetate, a new topical corticosteroid, was generally more potent than three high potency reference standards (fluocinonide, beta-methasone 17-valerate and fluocinolone acetonide) when the compounds were dissolved in 95% alcohol and applied in vasoconstrictor assays in healthy volunteers. On the basis of additional vasoconstrictor assay results, a 0-05% concentration of the steroid in a cream vehicle containing 15% propylene glycol was developed for therapeutic evaluation. In a double-blind comparison in 384 patients with dermatoses, 0-05% diflorasone diacetate cream was as effective as 0-05% fluocinonide cream in the therapy of lesions of psoriasis or atopic/neurodermatitis.
D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy; D005443:Flumethasone / Q000494:pharmacology; D005446:Fluocinolone Acetonide / Q000494:pharmacology; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D014666:Vasomotor System / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide; D001623:Betamethasone; D005443:Flumethasone; C014477:diflorasone